Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05656183 · ClinicalTrials.gov registry record · NA
CardioSeq: Impact of WGS in Individuals With CVD
A NA study of Cardiovascular Diseases, sponsored by Illumina.
- Active
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 1
- Study location
NCT05656183 is a NA study of Cardiovascular Diseases that is active but no longer recruiting, run by Illumina. The registered enrollment target is 1,500 participants, below the 26,969-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05656183, a NA study of Cardiovascular Diseases, is active but no longer recruiting, sponsored by Illumina.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST TruGenome Cardiovascular Disease test
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2025-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05656183
The ClinicalTrials.gov registry entry for NCT05656183 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,969-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (94% lower). The listed sponsor is Illumina, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which TruGenome Cardiovascular Disease test is the first listed.
NCT05656183 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05656183 about?
NCT05656183 is a clinical study titled "CardioSeq: Impact of WGS in Individuals With CVD". This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both with...
What is the current status of trial NCT05656183?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2023-01-06. Estimated completion is 2025-06.
What conditions does trial NCT05656183 study?
This clinical trial studies the following conditions: Cardiovascular Diseases.
What interventions are being tested in trial NCT05656183?
The interventions under investigation include: TruGenome Cardiovascular Disease test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05656183?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05656183 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.